Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654831 · ClinicalTrials.gov registry record · Phase 1
FTIH of ECC5004 in Healthy and Diabetic Participants
A Phase 1 study, sponsored by Eccogene.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT05654831 is a Phase 1 study that has completed, run by Eccogene. The registered enrollment target is 69 participants.
The verdict
NCT05654831, a Phase 1 study, has completed, sponsored by Eccogene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus
Interventions
- DRUG Placebo
- DRUG ECC5004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05654831
The ClinicalTrials.gov registry entry for NCT05654831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eccogene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05654831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05654831 about?
NCT05654831 is a clinical study titled "FTIH of ECC5004 in Healthy and Diabetic Participants". This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus
What is the current status of trial NCT05654831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2022-12-01. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT05654831?
The interventions under investigation include: Placebo (DRUG), ECC5004 (DRUG).
Who is sponsoring clinical trial NCT05654831?
This trial is sponsored by Eccogene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.